Scholarly Articles (2015-2022)

Defects in fatty acid amide hydrolase 2 in a male with neurologic and -sychiatric symptoms (Canada/ USA) (full – 2015)
Increased Cortical Inhibition in Autism-Linked Neuroligin-3R451C Mice Is Due in Part to Loss of Endocannabinoid Signaling. (USA) (full – 2015)
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy) (full – 2015)
Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. (USA) (full – 2015)
Endocannabinoid Signaling in Autism. (Italy/ UK) (full – 2015)
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling (USA/ Japan) (full – 2015)
The basolateral amygdala γ-aminobutyric acidergic system in health and disease (USA) (full – 2015)
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy)
(full – 2015)
Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s
Chorea, Alzheimer’s Disease, and Others. (Spain) (download – 2015)
Endocannabinoids and Mental Disorders. (Italy) (partial preview – 2015)
p21-activated kinase 1 restricts tonic endocannabinoid signaling in the hippocampus (Canada / China) (full – 2016)
Endocannabinoid signaling in social functioning: an RDoC perspective. (USA) (full – 2016)
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. (Italy) (full – 2016)
Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder (USA) (full – 2016)
Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. (Canada/ USA) (full – 2016)
Functions of synapse adhesion molecules neurexin/neurexins and neurodevelopmental disorders. (Japan) (link to PDF – 2016)
Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit. (China) (download – 2016)
Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. (Ireland) (abst – 2016)
Cannabinoids in Pediatrics. (USA) (full – 2017)
Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. (Italy/ USA) (full – 2017)
Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention. (Saudi Arabia) (full – 2017)
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. (Italy) (full – 2017)
Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. (USA) (full – 2017)
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality? (France) (full – 2017)
Synaptic functions of endocannabinoid signaling in health and disease (USA/ France/ Italy) (full – 2017)
Treating a novel plasticity defect rescues episodic memory in Fragile X model mice (USA) (full – 2017)
Chronic Inflammatory Pain Impairs mGluR5-Mediated Depolarization-Induced Suppression of Excitation in the Anterior Cingulate Cortex. (China) (full -2017)
The Neurobiological Bases of Autism Spectrum Disorders The R451C-Neuroligin 3 mutation hampers the expression of long-term synaptic depression in the dorsal  striatum (Italy) (abst – 2017)
Plasma anandamide concentrations are lower in children with autism spectrum disorder (USA) (full – 2018)
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. (Italy) (full – 2018)
Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3R451C Mouse Model of Autism. (Australia/ New Zealand) (full – 2018)
Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders. (China/ Russia/ USA/ Germany) (full – 2018)
Sex specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling. (Italy) (full – 2018)
Role of Striatal Direct Pathway 2-Arachidonoylglycerol Signaling in Sociability and Repetitive Behavior. (USA) (full – 2018)
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study. (Israel) (link to PDF – 2018)
Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. (Spain) (link to PDF – 2018)
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder (Israel) (click “drcannabiscombr” for download – 2018)
Cannabinoids: just like any other medication? (UK) (article – 2018)
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. (Iran) (abst – 2018)
Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies. (USA) (abst – 2018)
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. (Israel) (full – 2019)
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. (UK/ USA) (full – 2019)
The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). (UK) (full – 2019)
Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire. (USA) (full – 2019)
Lower circulating endocannabinoid levels in children with autism spectrum disorder (Israel) (full – 2019)
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. (Italy/ UK) (full -2019)
Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment. (Canada) (full – 2019)
Molecular Pathology and Pharmacological Treatment of Autism Spectrum Disorder-Like Phenotypes Using Rodent Models. (Taiwan) (full – 2019)
The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism (USA) (full – 2019)
Current state of evidence of cannabis utilization for treatment of autism spectrum disorders (USA) (full – 2019)
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use (Brazil) (full – 2019)
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. (UK/ USA) (full – 2019)
Ethical Implications for Providers Regarding Cannabis Use in Children With Autism Spectrum Disorders. (USA) (click “aappublicationsorg” for full – 2019)
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. (USA) (link to PDF – 2019)
An endocannabinoid-regulated basolateral amygdala-nucleus accumbens circuit modulates sociability. (USA) (link to PDF- 2019)
Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoid mediated synaptic dysfunction in a valproic acid-induced rat model of Autism (Taiwan -abst–2019)
CB1 receptor antagonism in capuchin monkeys alters social interaction and aversive memory extinction. (Brazil/ Japan) (abst – 2019)
Role of the endocannabinoid system in neurological disorders. (China) (abst – 2019)
Synthetic cannabinoids and their impact on neurodevelopmental processes. (Portugal) (abst – 2019)
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment (Italy/ Sweden) (abst – 2019)
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. (Israel) (abst – 2019)
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? (Italy/ Netherlands) (full – 2020)
Medical Cannabis in Children. (Israel) (link to download – 2020)
Medicinal Use of Cannabis in Children and Pregnant Women. (Israel) (click “researchgate” for download – 2020)

Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies (Italy/Spain – full-2020)  
A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report (Canada – full–2020)
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review (Italy – full–2020)
Safety and Efficacy of Cannabis in Autism Spectrum Disorder (USA – summary–2020)
Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. (Portugal – abst–2020)
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience (USA – abst–2020)
Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story (Italy – abst–2020)
Cannabinoid treatment for autism: a proof-of-concept randomized trial (Israel/USA – full–2021)
Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder (China – full–2021)
Acupuncture and oxytocinergic system: The promising treatment for autism (China/USA – full–2021)
From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders? (Brazil – full-2021)
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence (Italy/ UK) (full – 2021)
Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious? (Italy/USA – full–2021)
Cannabis and cannabinoid use in autism spectrum disorder: a systematic review (Brazil) (full – 2021)
Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders. (Australia) (full – 2021)
Cannabidiol and Neurodevelopmental Disorders in Children. (Australia) (full – 2021)
Urinary proteome profiling for children with autism using data-independent acquisition proteomics. (China) (full – 2021)
Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. (Israel) (full – 2021)
Endocannabinoid System Unlocks the Puzzle of Autism Treatment via Microglia (China/ USA) (full – 2021)
Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder. (USA) (full – 2021)
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric
Disorders: Molecular Mechanisms and Targets. (Italy) (full – 2021)
Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a
propensity score-matched analysis. (UK) (full – 2021)
CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in
Turkey and reviews of the literature. (Turkey) (full – 2021)
Infodemiological Examination of Personal and Commercial Tweets About Cannabidiol:
Term and Sentiment Analysis. (USA) (full – 2021)
Communication and social interaction in the cannabinoid-type 1 receptor null mouse:
Implications for autism spectrum disorder. (France/ USA/ Italy/ Spain/ Belgium/ Germany)
(full – 2021)
Potential of cannabinoids as treatments for autism spectrum disorders. (USA)
(click “sciencedirect” for manuscript – 2021)
Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α,
induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
(USA) (abst – 2021)
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
(USA) (abst – 2021)
Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with
Commonly Used Medications. (USA) (abst – 2021)
Endocannabinoid markers in autism spectrum disorder: A scoping review of human
studies. (Canada) (abst – 2021)
The role of the endocannabinoid system as a therapeutic target for autism spectrum
disorder: Lessons from behavioral studies on mouse models. (France)
(abst – 2021)
Autism and associated disorders: cannabis as a potential therapy. (USA/ Ethiopia)
(full – 2022)
Clinical Data on Canabinoids: Translational Research in the Treatment of Autism
Spectrum Disorders. (Portugal) (full – 2022)
Medicinal Cannabis in Children and Adolescents with Autism Spectrum Disorder: A
Scoping Review. (Canada) (full – 2022)
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and controlled placebo clinical trial (Brazil) (full – 2022)
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. (Japan/ USA) (full – 2022)
Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. (Israel) (full – 2022)
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. (UK) (full – 2022)
Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study. (Canada) (full – 2022)
Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. (Israel) (full – 2022)
Editorial: Implications of gut-brain interactions for the effects of compounds derived from Cannabis or modulating the endocannabinoid system in physiological and pathological processes. (Italy/ USA/ Canada) (editorial – 2022)
The role of cannabinoids in neurodevelopmental disorders of children and adolescents (Portugal) (abst in English & Spanish – 2022)
Cannabidiol for the treatment of autism spectrum disorder: hope or hype? (Brazil) (abst – 2022)
Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder. (Jordan/ USA) (abst – 2022)

United States Patent 6630507

Cannabinoids as antioxidants and neuroprotectants